p = 0.006), primarily driven by reductions in non-fatal MI and major adverse limb events
GI side effects are common to both compounds but may be more pronounced with retatrutide
50-99-7, Fisher Scientific, Waltham, MA) were purchased from Fisher Scientific Company, Waltham, MA
Other TRIUMPH Trials Additional Phase 3 trials in the TRIUMPH program are ongoing: TRIUMPH-1: Retatrutide in obesity (general population), results expected 2026 TRIUMPH-2: Retatrutide in type 2 diabetes, results expected 2026 TRIUMPH-3: Retatrutide cardiovascular outcomes trial, results expected 2027 Visualize Your Retatrutide Journey See how retatrutide builds up in your system over time and compare different dosing protocols
Insulin Resistance or Metabolic Conditions People with significant insulin resistance may take longer to feel hunger changes because appetite signaling is already disrupted
Your weight loss has plateaued: If your weight loss stalls for several weeks despite consistent diet changed and increased physical activity along with your medication, a higher dose may be needed to re-stimulate your metabolism and appetite suppression
